Results 221 to 230 of about 92,728 (309)

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study. [PDF]

Cancer
Coste A, Sritharan N, Lok A, Tomowiak C, Ferrant E, Clavert A, Roos-Weil D, Bouclet F, Caillet A, Croizier C, Stocker N, Tchernonog E, Feugier P, Santagostino A, Hivert B, Michallet AS, De Guibert S, Lara D, Waultier-Rascalou A, Merabet F, Durand A, Bussot L, Laribi K, Dilhuydy MS, Lévy V, Quinquenel A.   +25 more
europepmc   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives. [PDF]

Eur J Haematol
Gaidano G, Danesi R.
europepmc   +1 more source

Treatment of advanced cutaneous squamous cell carcinoma with cemiplimab in elderly multimorbid patients – a case series

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Patryk Porebski, Katharina Amschler, Michael P. Schön, Kai‐Martin Thoms   +3 more
wiley   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

European Journal of Haematology, EarlyView.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo, Richard J. Simpson, Emmanuel Katsanis   +2 more
wiley   +1 more source

Mitochondrial heteroplasmy is a risk factor for the development of chronic lymphocytic leukemia. [PDF]

Nat Commun
Pasca S, Hong YS, Shi W, Puiu D, Lake NJ, Lek M, Guallar E, Arking DE, Gondek LP.   +8 more
europepmc   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Albumin activates the AKT signalling pathway and protects B-chronics lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis

, 2002
Palmqvist, L, Jones, DT, Ganeshaguru, K, Prentice, HG, Mehta, AB, Anderson, RJ, Bruckdorfer, KR, Jackson, TR, Low, SY, Wickremasinghe, RG, Hoffbrand, AV   +10 more
core  

Risk Factors of Blood Culture Positivity and Mortality in Bloodstream Infections: A Population‐Based Study of Patients With B‐Cell Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Background Bloodstream infections remain a major cause of mortality among cancer patients. Pathogen surveillance and risk stratification tools are key to improved management. This study describes trends in causative pathogens and explores risk factors for positive blood cultures (PBCs) and post‐infection mortality in cancer patients.
Mathias Holmsgaard Eskesen, Alexander Djupnes Fuglkjær, Tarec Christoffer El‐Galaly, Paw Jensen, Izabela Ewa Nielsen, Laurids Østergaard Poulsen, Mikkel Runason Simonsen, Kirstine Kobberøe Søgaard   +7 more
wiley   +1 more source